Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 6, 2011, Pages 1172-1189

  Kharmate, Geetanjali ^a   Rajput, Padmesh S ^a   Watt, Heather L ^b   Somvanshi, Rishi K ^a   Chaudhari, Nicole ^a   Qiu, Xiaofan ^a   Kumar, Ujendra ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Epidermal growth factor receptor; Heterodimerization; Mitogen activated protein kinases; Photobleaching fluorescence resonance energy transfer; Somatostatin; Somatostatin receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 5;

ARTICLE; CELL STRAIN HEK293; CELL SURVIVAL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; CYCLIN-DEPENDENT KINASE INHIBITOR P27; EPIDERMAL GROWTH FACTOR; HEK293 CELLS; HUMANS; IMMUNOPRECIPITATION; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, SOMATOSTATIN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOMATOSTATIN; TYRPHOSTINS;

EID: 79955646925     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.03.006     Document Type: Article

References (72)

1. Gullick W.J. The type 1 growth factor receptors and their ligands considered as a complex system. Endocr. Relat. Cancer 2001, 8:75-82.
2. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 2001, 37(Suppl 4):S3-S8.
3. Holbro T., Civenni G., Hynes N.E. The ErbB receptors and their role in cancer progression. Exp. Cell Res. 2003, 284:99-110.
4. DiGiovanna M.P., Stern D.F., Edgerton S.M., Whalen S.G., Moore D., Thor A.D. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J. Clin. Oncol. 2005, 23:1152-1160.
5. Kraus M.H., Popescu N.C., Amsbaugh S.C., King C.R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 1987, 6:605-610.
6. Osaki A., Toi M., Yamada H., Kawami H., Kuroi K., Toge T. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am. J. Surg. 1992, 164:323-326.
7. Suo Z., Risberg B., Kalsson M.G., Willman K., Tierens A., Skovlund E., Nesland J.M. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J. Pathol. 2002, 196:17-25.
8. Toi M., Tominaga T., Osaki A., Toge T. Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study. Breast Cancer Res. Treat. 1994, 29:51-58.
9. Dolan J.T., Miltenburg D.M., Granchi T.S., Miller C.C., Brunicardi F.C. Treatment of metastatic breast cancer with somatostatin analogues-a meta-analysis. Ann. Surg. Oncol. 2001, 8:227-233.
10. Hejna M., Schmidinger M., Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?. Ann. Oncol. 2002, 13:653-668.
11. Lamberts S.W., Krenning E.P., Reubi J.C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 1991, 12:450-482.
12. Pool S.E., Krenning E.P., Koning G.A., van Eijck C.H.J., Teunissen J.J.M., Kam B., Valkema R., Kwekkeboom D.J., de Jong M. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin. Nucl. Med. 2010, 40:209-218.
13. Schally A.V., Engel J.B., Emons G., Block N.L., Pinski J. Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Curr. Drug Deliv. 2011, 8:11-25.
14. Kumar U., Grigorakis S.I., Watt H.L., Sasi R., Snell L., Watson P., Chaudhari S. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res. Treat. 2005, 92:175-186.
15. Reubi J.C., Laissue J., Krenning E., Lamberts S.W. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J. Steroid Biochem. Mol. Biol. 1992, 43:27-35.
16. Watt H.L., Kumar U. Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells. Cancer Cell Intnl. 2006, 6:5.
17. Ben-Shlomo A., Melmed S. Somatostatin agonists for treatment of acromegaly. Mol. Cell. Endocrinol. 2008, 286:192-198.
18. Bousquet C., Guillermet J., Vernejoul F., Lahlou H., Buscail L., Susini C. Somatostatin receptors and regulation of cell proliferation. Dig. Liver Dis. 2004, 36(Suppl 1):S2-S7.
19. Baragli A., Alturaihi H., Watt H.L., Abdallah A., Kumar U. Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2: co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell. Signal. 2007, 19:2304-2316.
20. Grant M., Collier B., Kumar U. Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking. J. Biol. Chem. 2004, 279:36179-36183.
21. Grant M., Kumar U. The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regul. Pept. 2009, 159:3-8.
22. Somvanshi R.K., Billova S., Kharmate G., Rajput P.S., Kumar U. C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimerizations and signaling. Cell. Signal. 2009, 21:1396-1414.
23. Watt H.L., Kharmate G.D., Kumar U. Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. Cell. Signal. 2009, 21:428-439.
24. Rocheville M., Lange D.C., Kumar U., Patel S.C., Patel R.C., Patel Y.C. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000, 288:154-157.
25. Rocheville M., Lange D.C., Kumar U., Sasi R., Patel R.C., Patel Y.C. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem. 2000, 275:7862-7869.
26. Grant M., Patel R., Kumar U. The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J. Biol. Chem. 2004, 279:38636-38643.
27. Pfeiffer M., Koch T., Schroder H., Laugsch M., Hollt V., Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J. Biol. Chem. 2002, 277:19762-19772.
28. Cattaneo M.G., Taylor J.E., Culler M.D., Nisoli E., Vicentini L.M. Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells. FEBS Lett. 2000, 481:271-276.
29. Florio T., Thellung S., Arena S., Corsaro A., Bajetto A., Schettini G., Stork P.J. Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatatse SHP-2. J. Physiol. Paris 2000, 94:239-250.
30. Lahlou H., Guillermet J., Hortala M., Vernejoul F., Pyronnet S., Bousquet C., Susini C. Molecular signaling of somatostatin receptors. Ann. NY Acad. Sci. 2004, 1014:121-131.
31. Pola S., Cattaneo M.G., Vicentini L.M. Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity. J. Biol. Chem. 2003, 278:40601-40606.
32. Sharma K., Srikant C.B. Induction of wild-type p53 Bax and acidic endonuclease during somatostatin signaled apoptosis in MCF-7 human breast cancer cells. Int. J. Cancer 1998, 76:259-266.
33. Zhou T., Xiao X., Xu B., Li H., Zou Y. Overexpression of SSTR2 inhibited the growth of SSTR2-positive tumors via multiple signaling pathways. Acta Oncol. 2009, 48:401-410.
34. Hagemeister A.L., Sheridan M.A. Somatostatin inhibits hepatic growth hormone receptor and insulin-like growth factor I mRNA expression by activating the ERK and PI3K signaling pathways. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 295:R490-R497.
35. Hanson A., Poudyal D., Hagemeister A., Reindl K.M., Sheridan M.A. The ERK and PI3K signaling pathways mediate inhibition of insulin-like growth factor-1 receptor mRNA expression by somatostatin. Mol. Cell. Endocrinol. 2010, 315:57-62.
36. Luttrell L.M., Daaka Y., Lefkowitz R.J. Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr. Opin. Cell Biol. 1999, 11:177-183.
37. Daub H., Wallasch C., Lankenau A., Herrlich A., Ullrich A. Signal characteristics of G protein-transactivated EGF receptor. EMBO J. 1997, 16:7032-7044.
38. Prenzel N., Zwick E., Daub H., Leserer M., Abraham R., Wallasch C., Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999, 402:884-888.
39. Daub H., Weiss F.U., Wallash C., Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein coupled receptors. Nature 1996, 379:557-560.
40. Darmoul D., Gratio V., Devaud H., Laburthe M. Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J. Biol. Chem. 2004, 279:20927-20934.
41. Kallergi G., Agelaki S., Markomanolaki H., Georgoulias V., Stournaras C. Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells. Cell. Physiol. Biochem. 2007, 20:977-986.
42. Rexer B.N., Engelman J.A., Arteaga C.L. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 2009, 8:18-22.
43. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., Beijersbergen R.L., Mills G.B., van de Vijver M.J., Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
44. Florio T., Yao H., Carey K.D., Dillon T.J., Stork P.J. Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol. Endocrinol. 1999, 13:24-37.
45. Hukovic N., Panetta R., Kumar U., Patel Y.C. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 1996, 137:4046-4049.
46. G. Kharmate, P.S. Rajput, H.L. Watt, R.K. Somvanshi, N. Chaudhari, X. Qiu, U. Kumar, Dissociation of Epidermal Growth Factor Receptor and ErbB2 Heterodimers in the Presence of Somatostatin Receptor 5 Modulate Signaling Pathways, Endocrinology, en.2010-0940.
47. Kramer H.K., Onoprishvili I., Andria M.L., Hanna K., Sheinkman K., Haddad L.B., Simon E.J. Delta opioid activation of the mitogen-activated protein kinase cascade does not require transphosphorylation of receptor tyrosine kinases. BMC Pharmacol. 2002, 2:5.
48. Rohrer S.P., Schaeffer J.M. Identification and characterization of subtype selective somatostatin receptor agonists. J. Physiol. Paris 2000, 94:211-215.
49. Grant M., Alturaihi H., Jaquet P., Collier B., Kumar U. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol. Endocrinol. 2008, 22:2278-2292.
50. Madshus I.H., Stang E. Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking. J. Cell Sci. 2009, 122:3433-3439.
51. Willmarth N.E., Baillo A., Dziubinski M.L., Wilson K., Riese Ii D.J., Ethier S.P. Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cell. Signal. 2009, 21:212-219.
52. Esparis-Ogando A., Diaz-Rodriguez E., Montero J.C., Yuste L., Crespo P., Pandiella A. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol. Cell. Biol. 2002, 22:270-285.
53. Montero J.C., Ocana A., Abad M., Ortiz-Ruiz M.J., Pandiella A., Esparis-Ogando A. Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS ONE 2009, 4:e5565.
54. Kallergi G., Agelaki S., Kalykaki A., Stournaras C., Mavroudis D., Georgoulias V. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Br. Cancer Res. 2008, 10:R80.
55. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7:505-516.
56. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
57. Thomas P., Smart T.G. HEK293 cell line: a vehicle for the expression of recombinant proteins. J. Pharmacol. Toxicol. Meth. 2005, 51:187-200.
58. Melien O., Sandnes D., Johansen E.J., Christoffersen T. Effects of pertussis toxin on extracellular signal-regulated kinase activation in hepatocytes by hormones and receptor-independent agents: evidence suggesting a stimulatory role of G(i) proteins at a level distal to receptor coupling. J. Cell. Physiol. 2000, 184:27-36.
59. Luttrell D.K., Luttrell L.M. Signaling in time and space: G protein-coupled receptors and mitogen-activated protein kinases. Assay Drug Dev. Technol. 2003, 1:327-338.
60. Luttrell L.M. 'Location, location, location': activation and targeting of MAP kinases by G protein-coupled receptors. J. Mol. Endocrinol. 2003, 30:117-126.
61. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4:988-1004.
62. Rexer B.N., Ghosh R., Arteaga C.L. Inhibition of PI3K and MEK: it is all about combinations and biomarkers. Clin. Cancer Res. 2009, 15:4518-4520.
63. Srikant C.B., Shen S.H. Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells. Endocrinology 1996, 137:3461-3468.
64. Susini C., Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol. 2006, 17:1733-1742.
65. Colas B., Cambillau C., Buscail L., Zeggari M., Esteve J.P., Lautre V., Thomas F., Vaysse N., Susini C. Stimulation of a membrane tyrosine phosphatase activity by somatostatin analogues in rat pancreatic acinar cells. Eur. J. Biochem. 1992, 207:1017-1024.
66. Sharma K., Patel Y.C., Srikant C.B. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol. Endocrinol. 1999, 13:82-90.
67. Gan H.K., Walker F., Burgess A.W., Rigopoulos A., Scott A.M., Johns T.G. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. J. Biol. Chem. 2007, 282:2840-2850.
68. Zhu X.-F., Liu Z.-C., Xie B.-F., Li Z.-M., Feng G.-K., Yang D., Zeng Y.-X. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett. 2001, 169:27-32.
69. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
70. Wada T., Qian X., Greene M.I. Intermolecular association of the p185(neu) protein and EGF receptor modulates EGF receptor function. Cell 1990, 61:1339-1347.
71. Shankaran H., Wiley H.S., Resat H. Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response. Biophys. J. 2006, 90:3993-4009.
72. Saveanu A., Gunz G., Guillen S., Dufour H., Culler M.D., Jaquet P. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 2006, 83:258-263.